Patent intelligence · WO
WO 2025260042
CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1
CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1
Patent details — WO 2025260042
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 18, 2025
- Expiration
- Dec 13, 2045
- Applicant
- AMGEN INC [US]
- CPC classes
- A61K 31/ 7088 A I, A61K/31713
Quick answer
WO 2025260042 (CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1) is held by AMGEN INC [US]. Status: granted. Granted Dec 18, 2025. Expires Dec 13, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMGEN INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 7088 A I, A61K/31713
More from AMGEN INC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2026117667
DOSES DE TITRATION DE MARIDEBART CAFRAGLUTIDE
granted -
WO 2026112486
MÉTHODES DE TRAITEMENT DE L'OBÉSITÉ ET DES AFFECTIONS LIÉES À L'OBÉSITÉ
granted -
WO 2026102199
THÉRAPIE COMBINÉE D'UN INHIBITEUR DE PRMT5 ET DU DARAXONRASIB POUR UTILISATION DANS LE TRAITEMENT DU CANCER MTAP-NUL
granted -
US 20260125398
5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS
granted -
US 20260116972
CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
granted -
WO 2026075950
SCHÉMA POSOLOGIQUE POUR AGENT ANTI-DLL3
granted -
WO 2026072909
PROTÉINES DE LIAISON À FLT1 ET MÉTHODES D'UTILISATION
granted -
WO 2026060304
ADMINISTRATION SOUS-CUTANÉE D'UN AGENT ANTI-DLL3 POUR LE TRAITEMENT DU CANCER
granted
Frequently asked questions
What is US patent 2025260042?
WO 2025260042 (CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1) is held by AMGEN INC [US]. Status: granted. Granted Dec 18, 2025. Expires Dec 13, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025260042?
AMGEN INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025260042 expire?
Our index shows an expiration date of Dec 13, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.